# NCT05197192 (NCT05197192)

> A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05197192
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: German CLL Study Group
- Conditions: Chronic Lymphocytic Leukemia
- Interventions: Obinutuzumab; Venetoclax; Acalabrutinib
- Enrollment: 202
- Primary outcome: Progression-free survival (PFS)

## Commentary we found

- YouTube: 14
- Podcasts: 8
- X threads: 5

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct05197192

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05197192", "email": "<work email>"}; the inbox owner confirms by the emailed link.